













httpIncreased homocysteine and lipoprotein(a) levels
highlight systemic atherosclerotic burden in
patients with a history of acute coronary syndromes
Gabriele Cioni, MD, PhD,a Rossella Marcucci, MD, PhD,a Anna Maria Gori, MSc,a Serafina Valente, MD,a
Cristina Giglioli, MD,a Gian Franco Gensini, MD,a,b Rosanna Abbate, MD,a and
Maria Boddi, MD, PhD,a Florence, Italy
Background: Strong evidence supports an association between high levels of homocysteine (Hcy) and lipoprotein(a)
[Lp(a)] and an increased rate of ischemic vascular events.
Methods: The study population comprised 162 patients (50 women [30.9%]; age, 66.716 12.76 years) having a history of
acute coronary syndrome within 1 year who underwent fasting blood sampling, measurement of intima-media thickness
and pulse wave velocity at the common carotid and femoral arteries by Doppler ultrasound, and ankle-brachial index
measurement. Cutoff values were considered 0.9 mm and 1.2 mm for carotid and femoral intima-media thickness,
respectively; 12 m/s for pulse wave velocity; and <0.9 for ankle-brachial index. We included hypertension, dyslipidemia,
diabetes, overweight/obesity, smoking, and family history of cardiovascular disease in the count of traditional risk factors
(CRFs). Adding Hcy $15 mmol/L and Lp(a) $500 mg/L to CRFs, we obtained a new score, named TOTAL.
Results:On univariate analysis, Hcy and Lp(a) were significantly associated with presence of atherosclerotic extracoronary
lesions (for Hcy: b[ .934; standard error[ 0.178; P < .0001; for Lp(a): b[ .961; standard error[ 0.177; P < .0001)
and compliance alterations (for Hcy: odds ratio, 13.3; 95% confidence interval, 3.9-45.3; P < .0001; for Lp(a): odds ratio,
14.6; 95% confidence interval, 5.69-37.62; P < .0001). On multivariate analysis, Lp(a) and Hcy were significantly
associated with extracoronary atherosclerosis, even after correction for CRFs. The area under the curve of the TOTAL
score for both atherosclerosis and vascular compliance alterations was significantly higher than the area under the curve of
traditional CRFs plus only Hcy $15 mmol/L or plus Lp(a) $500 mg/L, separately added.
Conclusions: The addition of evaluation of Hcy $15 mmol/L and Lp(a) $500 mg/L to the traditional CRF count does
improve detection of systemic atherosclerotic burden of patients with acute coronary syndrome and can offer a new
opportunity to optimize secondary prevention. (J Vasc Surg 2016;64:163-70.)Recent evidence has shown that several plasma bio-
markers are higher in coronary artery disease (CAD)
patients with concomitant peripheral arterial disease
(PAD) than in patients with exclusive CAD.1 A role for
homocysteine (Hcy) and lipoprotein(a) [Lp(a)] has been
hypothesized but not clearly proved.2 Specifically, hyper-
homocysteinemia is an independent risk factor for both
PAD and CAD,3-5 and in secondary prevention, elevated
levels of Hcy were related to residual cardiovascular (CV)
risk in patients with acute coronary syndrome (ACS) inde-
pendently of the efficacy of statin treatment.6
Lp(a) levels are positively associated with CAD events,
and the Copenhagen City Heart Study showed a stepwise
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Only one population-based study reported a significant
association of Lp(a) and the risk of PAD.7 The combina-
tion of high Hcy and Lp(a) levels synergistically increases
the likelihood for development of CAD8 and may signifi-
cantly influence clinical outcome. No data are available
about the association of high Hcy and Lp(a) levels with
extracoronary atherosclerotic burden in ACS patients.
To test the hypothesis that high Hcy and Lp(a) levels
could be related to the severity of asymptomatic peripheral
atherosclerotic burden in ACS patients besides the occur-
rence of the traditional CV risk profile and the severity of
CAD, we evaluated subclinical extracoronary atheroscle-
rotic morphologic and functional damage by ultrasound
examination9-15 and the assay of Hcy and Lp(a) levels in
162 patients who in the last year had suffered a first ACS
event, asymptomatic for extracoronary atherosclerosis
involvement.METHODS
Study population. The study population consisted
of 162patients (50women [30.9%]; age, 66.716 12.76 years)
having a history of ACS within 1 year, including ST-segment
elevation myocardial infarction, non-ST-segment elevation
myocardial infarction, and unstable angina,16 asymptomatic
for extracoronary (carotid, inferior limb, renal, and aortoiliac163
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enrolled from July 2009 to December 2011 on an outpa-
tient basis at the Office for Vascular Function Assessment,
Department of Experimental and Clinical Medicine,
Careggi Hospital, Florence. All subjects gave written
informed consent to the collection and analysis of data.
The investigation was performed in accordance with the
Declaration of Helsinki. Clinical practice, presented as
the object of this study, represents the standard practice
of our center and did not require Institutional Review
Board approval.
The presence of cardiovascular risk factors (CRFs) was
assessed according to the current guidelines: male sex;
hypertension (systolic blood pressure [SBP] $140 mm
Hg or diastolic blood pressure [DBP] $90 mm Hg, ac-
cording to the guidelines of the European Society of
Hypertension and the European Society of Cardiology,
or taking an antihypertensive treatment17); hyperlipidemia
(total serum cholesterol level $160 mg/dL, according to
the Third Report of the National Cholesterol Education
Program and European Atherosclerosis Society 2012
guidelines, or taking lipid-lowering medication); diabetes
mellitus (treated with an oral hypoglycemic agent, insulin,
or both or having fasting glucose levels $126 mg/dL, in
agreement with the American Diabetes Association); family
history of cardiovascular disease (CVD) (having first- or
second-degree relatives with premature CV disease); and
smoking habit, considered as present smoking habit or
past from a period of <1 year.
According to the blood pressure values reported by the
guidelines for the management of high blood pressure
published in 2014, blood pressure control was considered
good when values #149/90 mm Hg were measured at
all control visits.17
According to the World Health Organization indica-
tions, a glycated hemoglobin (HbA1c) value of 6.5% has
been considered good.18
Study design. Patients were evaluated 1 year after the
ACS event. The follow-up was programmed within a
maximum interval of 15 days from the programmed data.
Clinical evaluation was performed in a quiet room and
consisted of a dedicated medical questionnaire; physical
examination with heart rate, arterial blood pressure,
and body mass index (BMI) measurement; and blood
sampling.
After the patient rested for at least 15 minutes in the
supine position, a single operator performed electrocardio-
graphic and ultrasound assessment. Exclusion criteria
comprised autoimmune, pulmonary, or hematologic disor-
ders; anxiety or depression; and history of alcoholism or
addiction.
Traditional CRFs and TOTAL CV score. We
considered traditional CRFs to be male sex; family history
of CVD; dyslipidemia or low-density lipoprotein choles-
terol (LDL-C) level $70 mg/dL; hypertension or SBP
$140 mm Hg and DBP$90 mmHg for nondiabetics and
SBP $120 mm Hg and DBP $80 mm Hg for diabetics;
BMI $25; diabetes; and smoking habit.For each patient, we calculated a CV risk score, which
we named the TOTAL score, by the addition of 1 point for
Hcy $15 mmol/L and Lp(a) $500 mg/L to the points
due to the presence of traditional CRFs (male sex, family
history of CVD, BMI $25, diabetes, not good blood
pressure control, LDL-C >70 mg/dL, or smoking habit).
Minimum and maximum score values are 0 and 9,
respectively.
Ultrasound assessment. All patients underwent ultra-
sound assessment by a MyLab 70 XVision machine equip-
ped with a 7.5 MHz linear probe (Esaote Medical Systems,
Rome, Italy). The system used dedicated software for
computerized measurement of intima-media thickness
(IMT) and arterial wall compliance (RF-data technology
involving RF Quality Intima-Media Thickness [RFQIMT]
and RF Quality Arterial Stiffness [RFQAS], Esaote Medical
Systems).
IMT of the right and left common carotid arteries was
measured in the 1-cm segment proximal to the carotid
dilation with B-mode ultrasonography, by computerized
probe using a 7.5 MHz transducer attached to a MyLab
70 XVision Esaote machine. Femoral IMT (f-IMT) was
measured in the far wall of a 1-cm-long arterial segment
proximal to the femoral bifurcation.
Arterial stiffness was expressed as local pulse wave
velocity (PWv) and the change in distensibility of the right
and left common carotid arteries and was measured in the
1-cm segment proximal to the carotid dilation. Femoral
PWv (f-PWv) was measured in the far wall of a 1-cm-
long arterial segment proximal to the femoral bifurcation.
The cutoff value for PWv at the common carotids and
femoral arteries was considered 12 m/s, according to
current literature.17
For each subject, the maximum carotid IMT (c-IMT)
or f-IMT and PWv values were used for statistical analysis.
According to the guidelines of the European Society
of Hypertension, c-IMT values$0.9 mm and f-IMT values
$1.2 mm were considered abnormal.17
The ankle-brachial index (ABI) was determined by
ultrasonographic method using a MyLab 70 XVision
machine equipped with a 7.5 MHz linear probe and an
aneroid sphygmomanometer with cuff inflators appropriate
for brachial circumference. SBP measurements of the
brachial, tibial posterior, and dorsalis pedis arteries were
taken on both sides of the limb. The ABI was calculated
as the ratio between the lowest ankle systolic pressure
and the highest brachial systolic pressure.17,19,20 ABI was
determined for each leg, and the lowest value was consid-
ered for analysis. ABI values <0.9 and >1.3 were consid-
ered abnormal.6,21,22
We called atherosclerotic lesions the presence of at least
one alteration of c-IMT or f-IMT, according to a previ-
ously defined cutoff.
Coronary artery atherosclerosis. Coronary angiog-
raphy was performed only at the acute event, 1 year before
the follow-up of this study, and it was not repeated at the
control visit. Data of coronary angiography were collected
from the medical history of every patient. The examination
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coronary lesions was determined by visual estimation or by
a quantitative coronary angiography program (Xcelera;
Philips Healthcare, Best, The Netherlands) at the discre-
tion of the interventional cardiologist performing the
procedure. Clinically significant CAD was defined as the
presence of a coronary lesion resulting in a lumen diameter
stenosis >75% in a major epicardial artery (left anterior
descending artery, left circumflex artery, right coronary
artery) or one of its major branches. Clinically significant
left main disease was defined as a lumen diameter stenosis
>50%.13
Patients were stratified according to the number of
involved vessels as follows: normal coronaries or nonob-
structive CAD (subjects not showing the criteria for
clinically significant CAD); one-vessel, two-vessel, and
three-vessel disease (subjects showing significant lesions
in one, two, and three vessels, respectively); and significant
disease of the left main coronary artery, independent of
concomitant lesions in other vessels.23
Blood collection. Venous blood samples were taken
from each patient in the morning, after an overnight fast,
and collected from the antecubital vein into evacuated plas-
tic tubes (Vacutainer).
Biohumoral parameters. Lp(a) was measured by
an immunonephelometric method (LPAX IMMAGE;
Beckman Coulter, Brea, Calif); values $500 mg/L were
considered abnormal. Hcy plasma values (free or linked
to proteins) were measured by immunoenzymatic assay
(fluorescence polarization immunoassay, IMx; Abbott
Laboratories, Oslo, Norway); values $15 mmol/L were
considered abnormal. Lipid profile was assessed by stan-
dard method.
Statistical analysis. Database construction and statisti-
cal analysis were performed with SPSS for Windows
(version 19; SPSS Inc, Chicago, Ill). Categorical variables
were expressed as frequencies and percentages; analysis
of data distribution was evaluated by c2 test (statistical sig-
nificance was for P < .05). Continuous variables were
expressed as mean value and standard deviation and me-
dian and range when appropriate.
According to the literature, normal values of ABI,
IMT, and PWv were considered, respectively, $0.9, <0.9
for c-IMT and <1.2 for f-IMT, and <12 m/s for both
carotid PWv (c-PWv) and f-PWv.
The nonparametric Mann-Whitney and Kruskal-Wallis
tests were used for analysis of unpaired data. Correlation
analysis was measured by using the Spearman correlation
test.
Univariate and multivariate logistic regression tests
were used to evaluate the association between independent
risk factors and vascular dysfunction. Regression coeffi-
cients and 95% confidence intervals (CIs) are presented.
A P value < .05 was considered to indicate statistical
significance. We used receiver operating characteristic
(ROC) curve analysis to evaluate the accuracy in discrimi-
nating the presence of peripheral atherosclerosis or
altered vascular compliance in the study population.ROC curves were performed using, as continuous variable,
the probability of the number of traditional CRFs and
the number of traditional CRFs plus Hcy $15 mmol/L
or Lp(a) $500 mg/L, or both, related to the presence
of atherosclerosis or altered vascular compliance in the
study population.
RESULTS
Demographic and clinical characteristics of the
study population. Clinical and biochemical features of
the study population are listed in Table I.
Of 162 patients, 129 (79.6%) showed at least one of
the traditional CRFs that did not match the target values
indicated by the European Society of Cardiology and
the European Atherosclerosis Society 2012 guidelines
for the optimization of CV management in high-risk
patients (Table I). One year after the ACS event, 74%
of patients had not stopped smoking and about 50%
showed BMI >25, LDL >70 mg/dL, and not good
HbA1c control.
All patients showed liver and renal function within
normal limits.
Nobody reported a new acute coronary event after
discharge from the coronary intensive care unit.
Coronary atherosclerosis. Regarding coronary artery
involvement, we compared data of coronary angiograms,
obtained at the acute cardiac event, with extracoronary
data and biochemical parameters, collected after 1 year.
In particular, 19 (11.5%) were one-vessel, 63 (39.1%)
were two-vessel, and the remaining 80 (49.4%) were three-
vessel CAD patients.
In our patients, the presence of traditional CRFs was
not associated with coronary lesion extension, with the
exception for smoking habit (odds ratio [OR], 1.9; 95%
CI, 1.02-4.4; P ¼ .046) and diabetes (OR, 7.2; 95% CI,
2.7-18.3; P ¼ .044).
We found an association between severity of CAD and
extracoronary atherosclerotic markers, such as ABI values
(one-vessel, 0.99 6 0.13; two-vessel, 0.89 6 0.20; three-
vessel, 0.79 6 0.13; P for trend ¼ .042), c-IMT
(1358 6 1019 mm, 1750 6 840 mm, and 2625 6
1117 mm, respectively; P for trend ¼ .039), and f-IMT
(1552 6 985 mm, 1995 6 978 mm, and 2710 6
615 mm; P for trend ¼ .047).
Lp(a) and Hcy levels progressively increased according
to CAD severity. One-vessel CAD patients showed lower
Hcy (5.26 2.5mmol/L) andLp(a) (157.76 347.9mg/L)
values than two-vessel (Hcy, 13.2 6 4.9 mmol/L;
Lp(a), 579.7 6 517.9 mg/L; P ¼ .001) and three-vessel
CAD patients (Hcy, 16.9 6 5.8; Lp(a), 845.2 6 474.5;
P < .0001).
On univariate logistic regression analyses, we found a
significant association between CAD severity and values
of Lp(a) $500 mg/L (OR, 7.2; 95% CI, 2.7-18.3;
P < .0001) and Hcy $15 mmol/L (OR, 12.8; 95% CI,
4.8-34.1; P < .0001). These associations remained sig-
nificant after adjustment for sex, age, overweight, nonop-
timal LDL and high-density lipoprotein values, diabetes,
Table I. Study population characteristics at the visit time
Clinical characteristics
Male 112 (69.1)
Age, years 66.71 6 12.76
Smoking cessation <1 year 10 (26.3)a
Smoking habitb 28 (17.3)
SBP, mm Hg 127.28 6 18.02
DBP, mm Hg 76.57 6 7.50
BP values >140/90 mm Hgb 42 (26.0)
BMI, kg/m2 26.25 6 3.67





Family history of CAD 54 (33)
Pharmacologic therapies
Antihypertensive therapy 162 (100)
ACE inhibitors 52 (32.1)
ATII blockers 30 (18.5)
Beta-blockers 61 (37.7)





Oral hypoglycemic agents 34 (21.0)
Biochemical parameters
LDL-C, mg/dL 98.11 6 34.33
LDL-C $70 mg/dLb 86 (53.1)
HDL-C, mg/dL 47.08 6 16.97
HDL-C #45 mg/dLb 77 (47.5)
Glycemia, nondiabetics, g/L 0.97 6 0.23
Glycemia, diabetics, g/L 1.47 6 0.58
Diabetics with not optimal HbA1c
c 16 (47.1)
Triglycerides, mg/dL 126 6 48
RBCs  1012/L 4.47 6 1.04
WBCs  109/L 5.76 6 1.65
Platelets  109/L 238 6 121
Hb, g/dL 13.8 6 2.4
Hct, % 38.9 6 6.2
Creatinine, mg/dL 0.9 6 0.45
AST, U/L 20 6 14
ALT, U/L 36 6 11
GGT, U/L 17 6 12
CK, U/L 201 6 152
Hcy, mmol/L 12.43 6 6.00
Hcy >15 mmol/L 58 (35.8)
Lp(a), mg/L 512.31 6 531.53
Lp(a) >500 mg/L 83 (51.2)
ACE, Angiotensin-converting enzyme; ALT, alanine transaminase; AST,
aspartate transaminase; ATII, angiotensin II; BMI, body mass index; BP,
blood pressure; CAD, coronary artery disease; CK, creatine kinase; DBP,
diastolic blood pressure; GGT, g-glutamyltransferase; Hb, hemoglobin;
HbA1c, glycated hemoglobin;Hct, hematocrit; Hcy, homocysteine;HDL-C,
high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; Lp(a), lipoprotein(a); OAT, oral antiplatelet therapy; PAD,
peripheral arterial disease; RBCs, red blood cells; SBP, systolic blood pres-
sure; WBCs, white blood cells.
Categorical variables are presented as number (%). Continuous variables are
presented as mean 6 standard deviation.
aPercentage of total smokers at the event (n ¼ 38).
bTraditional cardiovascular risk factors (CRFs) according to guidelines.
cPercentage of diabetics (n ¼ 34).
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smoking habit for Lp(a) (OR, 3.8; 95% CI, 1.3-11.8;
P ¼ .018) and Hcy (OR, 4.9; 95% CI, 1.6-15.8; P ¼ .007).Markers of extracoronary atherosclerosis and
vascular compliance. Table II shows the pattern of ul-
trasound morphologic and functional markers of extrac-
oronary atherosclerotic vessel damage in ACS patients.
Of 162 patients, 45 (27.7%) did not show carotid or
femoral atherosclerotic lesions (Table II). Age was signifi-
cantly related to ABI (r ¼ 0.272; P ¼ .001), c-IMT
(r ¼ 0.292; P < .0001), and c-PWv (r ¼ 0.284; P ¼
.001) pattern. No differences according to gender or dia-
betes diagnosis were found (Table III).
Patients with family history of CVD showed a marked
carotid and femoral involvement with respect to patients
without family history (c-IMT, 1.9 6 1.1 mm vs 1.3 6
0.9 mm [P < .0001]; f-IMT, 2.1 6 1.2 mm vs 1.3 6
0.9 mm [P ¼ .001], respectively) and the presence of
ABI <0.9 (P < .0001).
Patients with severe CAD, defined as three-vessel
impairment, had significantly higher prevalence of
extracoronary atherosclerotic lesion involvement (72/80
[90%] vs 40/82 [52.5%]; P < .0001) than patients
with one- or two-vessel CAD. On the univariate logistic
analyses, we found that severe CAD was associated
with extracoronary atherosclerosis (OR, 16.9; 95% CI,
2.2-131.4; P ¼ .007). After adjustment for CRFs, this
association remained significant (OR, 19.1; 95% CI,
2.2-164.3; P ¼ .007).
Hcy, Lp(a), and vascular impairment. The relation-
ships between Hcy and Lp(a) values and morphologic and
functional markers of atherosclerotic damage and ABI are
shown in Table II.
On the univariate logistic analyses, Hcy $15 mmol/L
and Lp(a) $500 mg/L were significantly associated with
CAD severity (Hcy: OR, 12.8; 95% CI, 4.8-34.1; P <
.0001; Lp(a): OR, 7.2; 95% CI, 2.9-18.3; P < .0001),
and these associations remained significant also after the
adjustment for CRFs for Hcy $15 mmol/L (OR, 5.2;
95% CI, 4.8-34.1; P ¼ .005).
IMT and PWv were significantly higher in patients with
Hcy $15 mmol/L and Lp(a) $500 mg/L than in patients
with normal Lp(a) and Hcy values (data not shown).
On univariate logistic analysis, Hcy $15 mmol/L and
Lp(a) $500 mg/L were significantly associated with the
presence of atherosclerotic extracoronary lesions (Hcy:
OR, 13.3; 95% CI, 3.9-45.3; P < .0001; Lp(a): OR,
14.6; 95% CI, 5.69-37.62; P < .0001) and compliance
alterations (Hcy: OR, 13.9; 95% CI, 6.2-31.2; P <
.0001; Lp(a): OR, 2.7; 95% CI, 1.4-5.1; P ¼ .003).
ROC curve analysis for TOTAL score showed a signif-
icantly higher area under the curve for the discrimination of
atherosclerosis (abnormal on at least one-side for c-IMT,
f-IMT, or ABI) and vascular compliance alterations
(c-PWv or f-PWv) in the study population in comparison
with only traditional CRFs (Table IV). Differences among
ROC curves are expressed in Table IV.
DISCUSSION
The novel finding of our study is that the contempora-
neous occurrence of high Lp(a) and Hcy levels was strictly
Table II. Instrumental markers expressed in the total population and according to the number of risk factors,
homocysteine (Hcy) and lipoprotein(a) [Lp(a)] levels, and TOTAL score
ABI c-IMT, mm f-IMT, mm c-PWv, m/s f-PWv, m/s
Total population
Variable 0.93 6 0.18 1.6 6 1.1 1.7 6 1.1 10.37 6 3.76 9.97 6 3.88
Impaired marker 70 (43.2) 91 (56.2) 82 (50.6) 49 (30.2) 58 (35.8)
Traditional CRFs
#2 (n ¼ 58) 1.01 6 0.18 1529.78 6 1013 1456.29 6 1060 8.77 6 2.58 8.95 6 2.89
3-4 (n ¼ 73) 0.90 6 0.17 1639.21 6 1018 1716.59 6 1137 10.28 6 4.23 10.42 6 3.97
>4 (n ¼ 31) 0.82 6 0.14 1868.27 6 1083 1956.67 6 919 11.92 6 3.68 10.63 6 4.97
P for trend value .001 .09 .024 .069 .26
Hcy
>15 mmol/L (n ¼
60)
0.83 6 0.15 1873.6 6 1023.2 2274.1 6 1289.8 12.8 6 3.96 12.24 6 4.2
<15 mmol/L (n ¼
102)
0.98 6 0.16 1427.1 6 1028.6 1340.3 6 883.02 8.8 6 2.74 8.7 6 3.1
P value <.0001 .001 <.0001 <.0001 <.0001
Lp(a)
>500 mg/L (n ¼ 87) 0.87 6 0.15 2095.7 6 1056.9 2074.5 6 1128.1 11.05 6 4.05 10.98 6 3.71
<500 mg/L (n ¼ 75) 0.99 6 0.17 1201.6 6 901.7 1212.9 6 1044.7 9.17 6 2.99 9.23 6 3.48
P value .001 <.0001 <.0001 .001 <.05
TOTAL score
#2 (n ¼ 45) 1.05 6 0.31 1373.68 6 1012 1279.74 6 526 8.98 6 2.77 8.72 6 2.65
3-4 (n ¼ 60) 0.95 6 0.19 1622.29 6 979 1799.21 6 1123 9.93 6 3.45 910.36 6 3.72
>4 (n ¼ 57) 0.82 6 0.15 1859.75 6 1212 1980.60 6 1113 12.71 6 4.90 12.43 6 4.29
P for trend value <.0001 .004 <.0001 <.0001 .003
ABI, Ankle-brachial index; CRFs, cardiovascular risk factors; c-IMT, carotid intima-media thickness; c-PWv, carotid pulse wave velocity; f-IMT, femoral artery
intima-media thickness; f-PWv, femoral artery pulse wave velocity.
Categorical variables are presented as number (%). Continuous variables are presented as mean 6 standard deviation. Bold values show statistically significant
P values.
Table III. Extracoronary markers of atherosclerosis according to gender and diabetes
ABI c-IMT, mm f-IMT, mm c-PWv, m/s f-PWv, m/s
Men (n ¼ 112; 69.1%)
Variable 0.96 6 0.24 1.62 6 1.3 1.70 6 1.1 10.42 6 3.93 10.11 6 4.03
Women (n ¼ 50; 30.9%)
Variable 0.92 6 0.17 1.61 6 0.8 1.68 6 1.1 10.21 6 2.89 9.94 6 3.84
Diabetics (n ¼ 34; 21.0%)
Variable 0.90 6 0.27 1.73 6 1.6 1.75 6 1.3 11.07 6 3.55 10.33 6 3.97
Nondiabetics (n ¼ 148; 79.0%)
Variable 0.93 6 0.16 1.67 6 1.4 1.77 6 1.7 10.26 6 3.49 9.91 6 3.72
ABI, Ankle-brachial index; c-IMT, carotid intima-media thickness; c-PWv, carotid pulse wave velocity; f-IMT, femoral artery intima-media thickness; f-PWv,
femoral artery pulse wave velocity.
Values are reported as mean 6 standard deviation. P values were not significant.
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systemic atherosclerotic damage when added to the pattern
of traditional CRFs (TOTAL score) and to CAD severity at
the acute event.
A high percentage of our ACS patients showed a scarce
control of traditional CRFs because of ongoing smoking,
BMI >25, poor control of hypertension, and glycemic pro-
file. Because the strongest CRFs are hypertension for cere-
brovascular disease and smoking and diabetes for PAD, the
demonstration of asymptomatic carotid and femoral vessel
damage could help in selecting those ACS patients at
high CV residual risk who especially need good control
of CRFs.24 Among investigated markers of systemic
atherosclerotic damage, ABI <0.9 was the marker withthe highest prevalence in our ACS patients and could
be proposed as the marker of choice for screening of
asymptomatic peripheral atherosclerotic damage in this
high-risk subpopulation.
In our ACS population, only a positive family history of
CAD was associated with systemic atherosclerotic damage.
Interestingly, the contemporaneous occurrence of high
Lp(a) and Hcy levels added to the traditional CRF pattern
(TOTAL score) highlighted the presence and severity of
subclinical systemic atherosclerotic damage better than
CAD severity. In our study, TOTAL score (traditional
CRFs plus high Hcy and Lp(a) levels) was strongly linked
to both morphologic and functional vessel damage due
to the increase in Hcy and Lp(a) values according to the
Table IV. Differences among receiver operating characteristic (ROC) curves in relation to atherosclerosis in the study
population
ROC curve, AUC (95% CI) AUC difference 95% CI difference P value
Atherosclerosis
CRFs vs 0.65 (0.53-0.76)a 0.05 0.08 to 0.03 .0001
CRFs þ Hcy 0.69 (0.59-0.78)b
CRFs vs 0.65 (0.53-0.76)a 0.08 0.10 to 0.06 <.0001
CRFs þ Lp(a) 0.69 (0.59-0.79)c
CRFs vs 0.65 (0.53-0.76)a 0.12 0.15 to 0.09 <.0001
CRFs þ Hcy þ Lp(a) 0.73 (0.64-0.83)d
CRFs þ Hcy vs 0.68 (0.58-0.78)b 0.05 0.07 to 0.03 <.0001
CRFs þ Hcy þ Lp(a) 0.73 (0.64-0.83)d
CRFs þ Lp(a) vs 0.69 (0.59-0.79)c 0.05 0.05 to 0.04 <.0001
CRFs þ Hcy þ Lp(a) 0.73 (0.64-0.83)d
Vascular compliance
CRFs vs 0.64 (0.54-0.76)e 0.10 0.11 to 0.08 <.0001
CRFs þ Hcy 0.72 (0.63-0.802)f
CRFs vs 0.64 (0.54-0.76)e 0.03 0.06 to 0.01 .0128
CRFs þ Lp(a) 0.65 (0.53-0.743)g
CRFs vs 0.64 (0.54-0.76)e 0.11 0.15 to 0.07 <.0001
CRFs þ Hcy þ Lp(a) 0.73 (0.65-0.814)h
AUC, Area under the curve; CI, confidence interval; CRFs, cardiovascular risk factors; Hcy, homocysteine; Lp(a), lipoprotein(a).
aP value ¼ .03.
bP value < .0001.
cP value ¼ .0002.
dP value < .0001.
eP value ¼ .02.
fP value < .0001.
gP value ¼ .002.
hP value < .0001.
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femoral arteries (Fig).
In primary CV prevention, the role of Hcy and Lp(a) as
lipid and thrombotic biomarkers in the individual CV risk
stratification was proposed but is still under debate; no
data are available for the use of Hcy values in residual
CV risk measurement in ACS patients, whereas a possible
association between high Lp(a) levels and a persistent
high CV risk in CV patients receiving statin therapy25,26
was proposed.
The strict association between high Lp(a) and Hcy
levels and positive family history of CV disease found
in our ACS patients strongly supports the role of the
genetic component in determining high levels of
both Hcy and Lp(a). Our findings do not allow us to
know what pathophysiologic mechanisms facilitating the
occurrence and progression of atherosclerotic damage
and recurrence of CV events could be associated with
high Lp(a) and Hcy levels, but proatherogenic, pro-
thrombotic, and antifibrinolytic activities were clearly re-
ported. Indeed, an amplification of oxidative stress,
promotion of endothelial cell necrosis and of monocyte
and macrophage migration with foam cell formation,
and expanding necrotic lipid core could all contribute
to the damage of the CV system27 associated with high
Hcy and Lpa levels.
According to recent advances, our data may prove
useful not only to optimize the stratification of patientsat increased risk of disseminated atherosclerosis but
also to identify those subgroups for whom conventional
therapies would not be able to correct the risk factors
effectively. In particular, ongoing studies28,29 showed
that proprotein convertase subtilisin kexin 9 (PCSK9)
monoclonal antibodies were able to reduce Lp(a) plasma
levels. Regarding the use of vitamin supplementation to
reduce CV risk, there are no convincing data that sup-
port a positive clinical effect by the reduction of Hcy
levels.
Dedicated studies are needed to investigate whether
high Lp(a) and Hcy levels that are associated with more se-
vere systemic atherosclerotic damage could also select the
ACS subpopulation with very high residual CV risk.
Limits. Our study is an observational investigation. A
prospective phase has been started to investigate the
possible clinical relevance of our findings in the calculation
of residual CV risk in ACS patients with high TOTAL score
and systemic atherosclerotic burden.
Among proposed lipid and thrombotic biomarkers of
CV risk we studied, Lp(a) and Hcy levels are not markers
of inflammation. It is possible that the addition of other
markers of CV risk to the calculation of TOTAL score
could improve the scoring of systemic atherosclerotic dam-
age in ACS patients.
The TOTAL score is not actually validated in an inde-
pendent population. A procedure of validation has been
started.
Fig. A and B, Homocysteine (Hcy) and lipoprotein(a) [Lp(a)] values according to different degrees of extracoronary
atherosclerosis. C and D, Hcy and Lp(a) values according to different degrees of vascular compliance. ABI, Ankle-
brachial index; c-IMT, carotid intima-media thickness; c-PWv, carotid pulse wave velocity; f-IMT, femoral artery
intima-media thickness; f-PWv, femoral artery pulse wave velocity.
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In our patients having a history of ACS within 1 year,
the contemporaneous occurrence of high Hcy and Lp(a)
levels added to the pattern of traditional CRFs (TOTAL
score) was strictly related to the presence and severity of
asymptomatic systemic morphologic and functional athero-
sclerotic damage that was detectable in about 50% of ACS
patients.
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